E Fund Management Co. Ltd. Makes New $161,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN)

E Fund Management Co. Ltd. purchased a new stake in Myriad Genetics, Inc. (NASDAQ:MYGN) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 11,752 shares of the company’s stock, valued at approximately $161,000.

Other large investors have also recently made changes to their positions in the company. Loomis Sayles & Co. L P grew its stake in Myriad Genetics by 153.7% in the third quarter. Loomis Sayles & Co. L P now owns 2,189,601 shares of the company’s stock valued at $59,973,000 after purchasing an additional 1,326,497 shares during the last quarter. Disciplined Growth Investors Inc. MN grew its position in shares of Myriad Genetics by 21.1% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock worth $69,226,000 after buying an additional 440,107 shares during the last quarter. Iron Triangle Partners LP purchased a new position in shares of Myriad Genetics in the 3rd quarter worth approximately $11,007,000. State Street Corp raised its stake in shares of Myriad Genetics by 8.3% during the 3rd quarter. State Street Corp now owns 4,703,442 shares of the company’s stock worth $128,827,000 after acquiring an additional 359,685 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in Myriad Genetics by 50.2% during the fourth quarter. Fisher Asset Management LLC now owns 905,209 shares of the company’s stock valued at $12,410,000 after acquiring an additional 302,367 shares during the last quarter. 99.02% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Craig Hallum initiated coverage on Myriad Genetics in a research report on Wednesday, February 12th. They set a “buy” rating and a $29.00 price target on the stock. Leerink Partnrs downgraded Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. UBS Group decreased their price target on Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating for the company in a research note on Tuesday, February 25th. Morgan Stanley dropped their price target on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Monday, November 18th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $19.00 price objective (down from $27.00) on shares of Myriad Genetics in a research report on Tuesday, February 25th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $21.82.

Myriad Genetics Trading Down 3.2 %

Shares of NASDAQ:MYGN opened at $10.18 on Monday. The business’s 50 day moving average price is $12.95 and its 200-day moving average price is $18.29. Myriad Genetics, Inc. has a 1 year low of $9.76 and a 1 year high of $29.30. The firm has a market capitalization of $929.53 million, a price-to-earnings ratio of -7.83 and a beta of 1.79. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). The business had revenue of $210.60 million for the quarter, compared to analysts’ expectations of $210.35 million. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. During the same period in the prior year, the company posted ($0.12) EPS. On average, equities research analysts forecast that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.